Comparison of early hemodynamic performance of 3 aortic valve bioprostheses

Murat Ugur, Rakesh M Suri, Richard C Daly, Joseph A Dearani, Soon J Park, Lyle D Joyce, Harold M Burkhart, Kevin L Greason, Hartzell V Schaff
Journal of Thoracic and Cardiovascular Surgery 2014, 148 (5): 1940-6

OBJECTIVE: The study objective was to determine whether the new-generation Trifecta (St Jude Medical Inc, St Paul, Minn) bovine aortic valve bioprosthesis, which is designed for supra-annular positioning, produces early postoperative hemodynamic results comparable to or better than those of the Mitroflow (Sorin Group, Milan, Italy) or Perimount Magna (Edwards Lifesciences Corp, Irvine, Calif) bovine aortic valve bioprostheses.

METHODS: We retrospectively reviewed the medical records of patients who underwent aortic valve replacement with a Trifecta, Mitroflow, or Perimount Magna bovine pericardial prosthesis at Mayo Clinic between June 2007 and December 2012 and analyzed early postoperative hemodynamic performance by Doppler echocardiography.

RESULTS: A total of 1436 patients underwent aortic valve replacement (Trifecta in 196, Mitroflow in 1135, Perimount Magna in 105). Preoperative characteristics and early clinical outcomes were similar among the 3 valve groups. The average mean gradients were lower and valve areas were greater with the Trifecta valves. For the Trifecta, Mitroflow, and Perimount Magna valves, the average mean gradient was 11.4 mm Hg, 16.9 mm Hg, and 14.1 mm Hg, respectively; the effective orifice area was 2.22 cm2, 1.85 cm2, and 2.09 cm2, respectively; and the indexed effective orifice area was 1.14 cm2/m2, 0.96 cm2/m2, and 1.07 cm2/m2, respectively (all P<.001). Similar statistical significance was found when data were stratified by valve size. Severe prosthesis-patient mismatch (indexed effective orifice area<0.60 cm2/m2) was detected in 1.3% of patients (n=2/150) with the Trifecta, 5.8% of patients (n=44/758) with the Mitroflow, and 3.2% of patients (n=3/95) with the Perimount Magna (P=.048).

CONCLUSIONS: Early hemodynamic postoperative performance of the Trifecta bioprosthesis is favorable. Additional follow-up should determine whether these small hemodynamic differences will persist and influence later clinical outcomes.

Full Text Links

Find Full Text Links for this Article


You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"